** Shares of drugmaker AbbVie ABBV.N rise 2.7% to $185.3 premarket
** AbbVie raises its 2025 profit forecast after better-than-expected sales of its newer immunology drugs Skyrizi and Rinvoq help it beat quarterly earnings expectations
** Company expects its annual adjusted profit to be between $12.09 and $12.29 per share, up from its previous estimate of $11.99 to $12.19
** ABBV earns adj. Q1 profit of $2.46 per share, compared with analysts' average expectation of $2.38
** As of last close, ABBV had risen 1.5% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.